ArticleClinical medicine. Pathology2008
Combined hepatocellular cholangiocarcinomas; analysis of a large database.
Article in Clinical medicine. Pathology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- A Case of Combined Hepatocellular-Cholangiocarcinoma Diagnosis and Treatment With Literature Review.Clinical case reports · 2025Article
- Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.Journal of cancer research and clinical oncology · 2024Review
- Update on the Diagnosis and Treatment of Combined Hepatocellular Cholangiocarcinoma.Journal of clinical and translational hepatology · 2024Review
- Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.Journal of cancer research and clinical oncology · 2023Article
- Review
- Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study.Frontiers in oncology · 2023Article
- Combined Hepatocellular-Cholangiocarcinoma: An Update on Pathology and Diagnostic Approach.Biomedicines · 2022Review
- Development and Validation of Nomogram for Predicting Survival of Primary Liver Cancers Using Machine Learning.Frontiers in oncology · 2022Article
- Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma.Cancers · 2021Review
- Update on Pathologic and Radiologic Diagnosis of Combined Hepatocellular-Cholangiocarcinoma.Journal of liver cancer · 2021Review
- Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma.World journal of hepatology · 2020Article
- The clinicopathological features of combined primary hepatic adenosquamous-hepatocellular carcinoma.International journal of clinical and experimental pathology · 2020Article
- Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocholangiocarcinoma.Therapeutic advances in gastroenterology · 2020Article
- Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma.Frontiers in oncology · 2020Review
- Combined hepatocellular-cholangiocarcinoma: a population level analysis of incidence and mortality trends.World journal of surgical oncology · 2019Article
- Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions.Journal of hepatocellular carcinoma · 2019Review
- Synchronous cancers of gallbladder carcinoma and combined hepatocellular cholangiocarcinoma: an unusual case and literature review.BMC cancer · 2018Review
- Hepatocholangiocarcinoma/intrahepatic cholangiocarcinoma: are they contraindication or indication for liver transplantation? A propensity score-matched analysis.Hepatology international · 2018Article
- Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study.British journal of cancer · 2018Article
- Importance of surgical margin in the outcomes of hepatocholangiocarcinoma.World journal of hepatology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimCombined hepatocellular cholangiocarcinoma (combined tumor) has been described as either a variant of hepatoma or a variant of cholangiocarcinoma. Prior studies evaluated fewer than 50 patients with combined tumors, precluding multivariate analyses. Posited was the notion that analysis of a large database would yield more definite answers.
methodsThis study used SEER (Surveillance, Epidemiology, and End Results Program of the National Cancer Institute) to analyze 282 combined tumors, 2,035 intrahepatic cholangiocarcinomas, and 19,336 hepatomas between the years 1973-2003. Multinomial logit regression calculated point estimates and 95% confidence intervals (c.i.) for relative risk (rr). Cox regression calculated point estimates and 95% confidence intervals (c.i.) for hazard ratios (ĥ).
resultsMen less often had cholangiocarcinomas than they had combined tumors (rr = 0.63, c.i. = 0.49-0.81). Hepatomas less often than combined tumors presented with distant spread (rr = 0.56, c.i. = 0.43-0.72). Men (rr = 1.50, c.i. = 1.17-1.93) and patients with a known Asian or Pacific birthplace (rr = 2.36, c.i. = 1.56-3.56) more often had hepatomas than they had combined tumors. Among patients not known to have an Asian/Pacific birthplace, a diagnosis of cholangiocarcinoma (ĥ = 0.72, c.i. = 0.63-0.82) or hepatoma (ĥ = 0.75, c.i. = 0.66-0.86) provided a better prognosis than did a diagnosis of combined tumor.
conclusionCombined tumors differ from hepatomas and cholangiocarcinomas in terms of distribution and survival patterns in the population; they should be considered neither cholangiocarcinomas nor hepatomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.